ENDPOINTS

Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drug

Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer drug, which was brushed to the side last year as it focused resources on developing a next-generation lung cancer therapy. Servier will pay ...

Mar 19, 2025 - 12:01
 0
Servier pays $70M upfront for Black Diamond’s RAS- and RAF-targeted cancer drug
Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer drug, which was brushed to the side last year as it focused resources on developing a next-generation lung cancer therapy. Servier will pay ...
Read More

Tags:

Previous Article

Flagship's Ampersand gets Eli Lilly's support in $65M Series B

Next Article

Flagship’s Ampersand Bio Adds $65M to Solve One of the Top Challenges in Medicine

Related Posts

Emalex clears Phase 3 for Tourette syndrome, will seek FDA approval

Emalex clears Phase 3 for Tourette syndrome, will seek ...

Feb 25, 2025  0

Charles River’s $1B revenue; Theratechnologies restarts HIV drug supply

Charles River’s $1B revenue; Theratechnologies restarts...

Feb 20, 2025  0

Pliant shares plummet as Phase 2b lung fibrosis study paused

Pliant shares plummet as Phase 2b lung fibrosis study p...

Feb 10, 2025  0